Calton & Associates’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,220
| Closed | -$235K | – | 287 |
|
|
2022
Q3 | $235K | Sell |
2,220
-53
| -2% | -$5.61K | 0.13% | 170 |
|
|
2022
Q2 | $221K | Sell |
2,273
-119
| -5% | -$11.6K | 0.12% | 198 |
|
|
2022
Q1 | $224K | Buy |
+2,392
| New | +$224K | 0.07% | 311 |
|
|
2021
Q4 | – | Sell |
-2,263
| Closed | -$217K | – | 397 |
|
|
2021
Q3 | $217K | Sell |
2,263
-18
| -0.8% | -$1.73K | 0.05% | 361 |
|
|
2021
Q2 | $222K | Sell |
2,281
-70
| -3% | -$6.81K | 0.04% | 363 |
|
|
2021
Q1 | $229K | Sell |
2,351
-1
| -0% | -$97 | 0.04% | 348 |
|
|
2020
Q4 | $225K | Buy |
+2,352
| New | +$225K | 0.04% | 343 |
|
|
2020
Q3 | – | Sell |
-1,875
| Closed | -$229K | – | 362 |
|
|
2020
Q2 | $229K | Buy |
+1,875
| New | +$229K | 0.05% | 271 |
|
|
2020
Q1 | – | Sell |
-1,995
| Closed | -$215K | – | 355 |
|
|
2019
Q4 | $215K | Buy |
+1,995
| New | +$215K | 0.04% | 326 |
|